Trial Profile

A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eclitasertib (Primary)
Indications COVID-19 respiratory infection
Focus Therapeutic Use
Sponsors Sanofi

Most Recent Events

03 May 2021 Results published in the Denali Therapeutics Inc Media Release.
03 May 2021 Acccording to a Denali Therapeutics Inc media release, the study did not meet its primary endpoint.
03 May 2021 Acccording to a Denali Therapeutics Inc media release, the company announced in February to cease further development of DNL758 in COVID-19 based on the rapidly evolving landscape of treatment and prevention options for COVID-19.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com